Multi-drug resistant tuberculosis burden and risk factors: An update

Kathmandu University Medical Journal

Volumn 8, Issue 29, 2010, Pages 116-125

  Marahatta, S B ^a  

^a KATHMANDU UNIVERSITY SCHOOL OF MEDICAL SCIENCES   (Nepal)

Author keywords

Dots plus; Multi drug resistant (MDR) tuberculosis burden; Risk factors

Indexed keywords

TUBERCULOSTATIC AGENT;

ATTITUDE TO ILLNESS; CONTROL STRATEGY; DRUG SENSITIVITY; GENETIC PREDISPOSITION; HEALTH BEHAVIOR; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; QUALITY CONTROL; REVIEW; RISK FACTOR; SHORT COURSE THERAPY; SOCIAL STATUS; SOUTHEAST ASIA; TREATMENT DURATION; TUBERCULOSIS CONTROL;

EID: 77953655525     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: 10.3126/kumj.v8i1.3234     Document Type: Review

References (61)

1. Sharma SK, Mohan A. Multidrug-Resistant Tuberculosis. Chest. 2006;130:261-72.
2. World Health Organization. WHO report 2007: global tuberculosis control, surveillance, planning, financing. Geneva: World Health Organisation; 2007.
3. World Health Organization. WHO report 2008; global tuberculosis control, surveillance, planning, financing. Geneva: World Health Organisation; 2008.
4. Zager EM, MCNerney R. BMC. Infectious Disease.2008;8:10.
5. Dye C, Williams BG. Slow elimination of Multidrug-Resistant Tuberculosis Sci Transl Med. 2009.
6. Fox W, Ellard, GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3: 231-79.
7. Wolinksy E, Reginster A, Steenken, W. Drug resistant tubercle bacilli in patients under treatment with streptomycin. Am Rev Tuberc. 1948; 58:335.
8. Jassal M, Bishai WR. Extensively drug- resistant tuberculosis. Lancet Infect Dis. 2009;9:19-30.
9. Rich M. Diagnosis and Treatment of Multidrug-Resistant Tuberculosis. In Tuberculosis: A Comprehensive, International Approach. Raviglione MC, editor. New York: Informa Healthcare USA; 2006 417-458.
10. Warner DF, Mizrahi V. Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clinical Microbiology Reviews. 2006;19:558-70.
11. Farmer P, Robin S, Ramilus SL, et al. Tuberculosis, poverty, and "compliance": lessons from rural Haiti. Sem Resp Inf. 1991;6:254-60.
12. Farmer P. Social scientists and the new tuberculosis. Soc Sci Med. 1997;43:347-58.
13. Cegielski P, Blondal-Vink K, Lambregts-van Weezenbeek K, et al. Programmatic Control of Multidrug-Resistant Tuberculosis. Raviglione MC (editor). In Tuberculosis: A Comprehensive, International Approach. New York: Informa Healthcare USA; 2006.
14. Pearson ML, Jereb JA, Frieden, TR, et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Annals of Internal Medicine. 1992;117:191-6.
15. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. New Engl J Med. 1993;328:521-6
16. Moss AR, Alland D, Telzak E et al. A city-wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis. 1997;1:115-21.
17. Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City--turning the tide. New Engl Journ Med. 1995; 333:229-33.
18. Moro ML, Gori A, Errante I, et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS. 1998;12:1095-102.
19. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Inf Dis. 2003;3:432-42.
20. Grimaldo ER, Tupasi, TE, Rivera AB, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. International Journal of Tuberculosis & Lung Disease. 2001;5:546-50.
21. Sterling TR. The WHO/IUTALD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. Int J Tuberc Lung Dis. 2004;8:1396-400.
22. Bishai WR, Graham NM, Harrington S, et al. rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. New Engl J Med. 1996; 334:1573-6.
23. Ridzon R, Whitney CG, McKenna, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Resp Crit Care Med. 1998;157:1881-4.
24. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: WHO; 2006
25. Meier A, Sander P, Schaper KJ, et al. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrobial Agents & Chemotherapy, 1996; 40:2452-4.
26. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: WHO; 2006
27. Aziz MA,WrightA, LaszloA, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-Tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006;368:2142-54.
28. WHO/IUALTD. Anti-tuberculosis drug resistance in the world: fourth global report. Geneva: WHO/IUTALD; 2008.
29. Wright A, Zignol M, Deun AV et al. Epidemiology of drug resistance 2002-07 -an updated analysis of the Global Project on Anti-tuberculosis Drug Resistance Surveillance. Lancet. 2009;373:1861-73.
30. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000- 2004. MMWR - Morbidity & Mortality Weekly Report. 2006; 55:301-5.
31. Gandhi NR, Moll A, SturmAW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80.
32. DeRiemer K, Garcia-Garcia L, Bobadilla-del-Valle M, et al. Does DOTS work in populations with drug-resistant tuberculosis. Lancet. 2005;365:1239-45.
33. Blower SM, Chou T. Modelling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med. 2004;10:1111-6.
34. Yong Kim J, Shakow A, Mate K, et al. Limited good and limited vision: multidrug-resistant tuberculosis and global health policy. Soc Scien Med. 2005;61:847-59.
35. Harvard Medical School/Open Society Institute. The Global Impact of Drug Resistant Tuberculosis. Boston: Program in Infectious Disease and Social Change. USA: Harvard Medical School; 1999.
36. Gupta R, Cegielski JP, Espinal MA, et al. Increasing transparency for health: introducing the Green Light Committee; Trop Med Int Health. 2002;7: 970-6.
37. Carpenter JL, Obnibene AJ, Gorby EW, et al. Antituberculosis drug resistance in south Texas; Am Rev Respir Dis. 1983; 128: 1055-8.
38. Weyer K, Kleeberg HH. Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of a continuous national drug resistance surveillance programme involvement; Tuber Lung Dis. 1992;73:106-12.
39. Sharma SK, Turaga KK, Balamurugan A, et al. Clinical and genetic risk factors for the development of multidrugresistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infect Genet Evol. 2003;3: 183-8.
40. Kato-Maeda M, Rhee JT, Gingeras TR, et al. Comparing genomes within the species Mycobacterium tuberculosis; Genome Res. 2001;11: 547-55.
41. Ramaswamy S, Musser JM. Molecular genetic basis of anti-microbial agent resistance in Mycobacterium tuberculosis update. Tuber. Lung Dis. 1998;79: 3-29.
42. Sharma SK and Mohan A.Multidrug-resistant tuberculosis; Indian J Med.Res. 2004;120:354-76.
43. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993; 329:784-91.
44. Mwinga A. Drug resistant tuberculosis in Africa; Ann N Y Acad Sci. 2001;953:106-12
45. Datta M, Radhamani MP, Selvaraj R, et al. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. Tuber Lung Dis. 1993;74:180-6.
46. Johnson J, Kagal A, Bharadwaj R. Factors associated with drug resistance in pulmonary tuberculosis; Indian J Chest Dis Allied Sci. 2003;45:105-9.
47. Drobniewski FA, Balabanova YM. The diagnosis and management of multiple-drug-resistant tuberculosis at the beginning of the new millennium; Int J Infect Dis. 2002;6:21-31.
48. Prasad R. MDR TB: Current Status. Indian J Tuberc. 2005;52:121-31.
49. Casal M, Vaquero M, Rinder H, et al. A Case-Control Study for Multidrug-Resistant Tuberculosis: Risk Factors in Four European Countries. Microb Drug Resist. 2005;1: 62-9.
50. Faustini A, Hall AJ, Perucci C et al. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review Thorax. 2006;61;158-63.
51. Ruddy M, Balabanova Y, Graham C et al. Rates of drug resistance and risk factor analysis in civilian and prison patient with tuberculosis in Samara Region, Russia Thorax. 2005;60:130-5.
52. Pande JN, Singh UB, Sinha S et al. Evaluation of risk factors and prevalence of drug resistant tuberculosis in North India. Chest. 2002;128 (4):404S.
53. Suarez-Garcia I, Rodriguez-Blanco A, Vidal-Perez JL et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain Eur J Clin Microbiol Infect Dis. 2009;28:325-30.
54. Barroso EC, Salani Mota, RM, Santos RO, et al. Risk factors for acquired multidrug-resistant tuberculosis J Pneumologia. 2003; 29:989-97.
55. Law WS, Yew WW, Chiu leung C, et al. Risk factors for multidrug-resistant tuberculosis in Hong Kong International journal of tuberculosis and lung disease. 2008; 12; 1065-70.
56. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. New Eng J Med. 2003; 348:119-28.
57. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Inf Dis. 2006;12:1389-97
58. Drobniewski F. Is death inevitable with multiresistant TB plus HIV infection? Lancet. 1997;349:71-2.
59. Van der Wal M, Weyer K, Lancastre, J. A standardised approach to management of drug-resistant TB in South Africa. South Africa Medical Research Council Expert Consultation on Drug-Resistant Tuberculosis; 2006 Johannesbergn.
60. Leimane V. MDR-TB and XDR-TB Management in Latvia. Meeting of the Global XDR-TB Task Force; 2006; Geneva.
61. Resch SC, Salomon JA, Murray M, Weinstein MC. Cost effectiveness of treating multidrug-resistant tuberculosis. PLoS Med. 2006;3:241-5.